MIRA
INFORM REPORT
|
Report Date : |
04.07.2007 |
IDENTIFICATION DETAILS
|
Name : |
CAPSUGEL – DIVISION OF PFIZER INC. |
|
|
|
|
Registered Office : |
235, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
30.04.2006 |
|
|
|
|
Date of Incorporation : |
02.06.1942 |
|
|
|
|
Legal Form : |
Corporation - Public |
|
|
|
|
Line of Business : |
Subject is engaged in the development and production of various
drugs and medicines for humans and animals. |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
IDENTIFICATION & EXECUTIVE
SUMMARY
Company Name : PFIZER INC.
Address :
City :
State/Province :
In KUSD As of : 30/04/2006
Zip Code : 10017
Sales / Revenue : 104,241
Country : UNITED STATES
Net Income : 100,688
Telephone : 212 733-2323
Total Equity : 919,156
Facsimile : 212 883-4873
Legal Form : Corporation - Public
Website :
www.pfizer.com
Business Activity : Pfizer Inc. is engaged as a provider of prescription and over-the-counter
medicines for humans and animals.
NOTE TO CLIENT
Contact: Investor Relations. Information in the report was taken from the Company's 2006 Annual Reportfiled with the Securities and Exchange Commission.
--
NOTE: WITH REGARD TO THE
ORDERED NAME CAPSUGEL DIVISION OF WARNER- LAMBERT CO. PLEASED BE ADVISSED THAT
CAPSUGEL IS REPORTED TO BE A DIRECT DIVISION OF PFIZER INC. THE PROVIDED
ADDRESS;
An exact employee number for the
As of December 31, 2006, the Company employed approximately 98,000 people in their operations throughout the world. On January 22, 2007, the Company announced, as a part of its priorities to drive improved performance, position the Company for future success and enhance total shareholder return, a plan to eliminate about 10,000 positions, or about 10% of Pfizer’s worldwide workforce, by the end of 2008.
--
Shareholders over 5% were not reported.
LEGAL
Legal Form : Corporation - Public
Since (D/M/Y) : 02/06/1942
State/Province of Incorporation : DE
Status : ACTIVE
Previous Legal Form :
Company is NOT required to publish an annual financial report.
The Company is incorporated in
File Number : 0383418
Incorporation Date / Formation Date : 06/02/1942 (mm/dd/yyyy)
Entity Name : PFIZER INC.
Entity Kind : CORPORATION
Entity Type : GENERAL
Residency : DOMESTIC
State : DE
REGISTERED AGENT
INFORMATION
Name : THE CORPORATION TRUST COMPANY
Address :
CORPORATION TRUST CENTER
City :
County : NEW CASTLE
State : DE
Postal Code : 19801
Phone : (302)658-7581
--
NAME : PFIZER INC.
DOMESTIC/FOREIGN : Foreign
STATUS : Good Standing
STATE OF
ORGANIZATION :
For Profit
REGISTERED AGENT NAME : C T CORP SYSTEM
ADDRESS :
CITY :
STATE : SC
ZIP : 29601 0000
FILE DATE : 02/29/2000
EFFECTIVE DATE : 02/29/2000
---
PFIZER INC.
Initial DOS Filing Date : JUNE 25, 1951
County :
Jurisdiction :
Entity Type : FOREIGN BUSINESS CORPORATION
Current Entity Status : ACTIVE
C/O C T CORPORATION SYSTEM
111
Principal Executive
Office
PFIZER INC.
Registered Agent
C T CORPORATION SYSTEM
111
----
Managers/Key Personnel
Mr. Jeffrey B. Kindler Chairman & Chief Executive Officer
Ms. Linzell Harris Vice President
Mr. Joseph Feczko - Chief Medical O Vice President
Ms. Loretta Cangialosi Vice President and Controller
Pfizer Inc.;
Share Volume 2,053,400
52 Wk High / Low $ 28.60 / $ 22.16
Shares Outstanding 7,018,263,000
Pfizer Inc. reports numerous world wide subsidiaries. Due to the Number, a few have been selected for review:
412357 Ontario Inc
A S Ruffel (
A.S. Ruffel (Private)
Limited
A/O Pfizer
Adenylchemie GmbH
Agouron Pharmaceuticals,
Inc
Alginate Industries (
American Food
Industries, Inc
Andean Services S.A
Angiosyn, Inc
Balverda S.R.L
BINESA 2002, S.L
Biocor Animal Health
Inc
Bioindustria
Farmaceutici S.R.L
Bioptics SARL
Bioren, Inc
Biosearch Manufacturing
S.r.l
Blue Whale Re Ltd
C.P. Pharmaceuticals
International C.V
Capsugel (
Capsugel
Capsugel de Mexico, S.
de R.L. de C.V
Capsugel
Capsugel Healthcare
Limited
Capsugel Japan Inc.
(KK)
Capsugel Ploermel
CARDEL
Centrofarma, Sociedad
Anonima
Ceuticlab Laboratorios de Produtos
Farmaceuticos, Lda.
Charlie Papa Operations,
LLC
CHC Direct LLC
Compania Farmaceutica
Upjohn, S.A.
Consumer Health Products
(Minority Interests)
Company
Continental
Farmaceutica, S.L.
Continental Pharma,
Inc.
Sociedad
Unipersonal
Distribuidora Mercantil
Centro
Duchem Laboratories
Limited
Esperion LUV
Development, Inc.
Esperion Therapeutics,
Inc.
Eversharp Canada
Inc.
Farminova Produtos Farmaceuticos de
Inovacao, Lda.
Farmitalia Carlo Erba
Limited
Farmogene Productos
Farmaceuticos Lda
Fyrcia HB
G. D. Searle &
G. D. Searle (
G. D. Searle
International Capital LLC
G. D. Searle LLC
Gödecke GmbH
Gödecke OTC Beteiligungs
GmbH
Greenstone Ltd.
Heinrich Mack Nachf.
GmbH. & Co. KG
Hepar Contribution
LLC
Heumann PCS GmbH
Idun Pharmaceuticals,
Inc.
International Affiliated
Corporation LLC
Inter-World Insurance
Company Limited
J B Tillott Limited
Jouveinal Holland
B.V.
Keystone Chemurgic
Corporation
Kiinteistö Oy Helsingin
Tietokuja
Kommanditbolaget Hus
Gron
Korea Pharma Holding
Company Limited
Laboratoires Pfizer
SA
Laboratorios Laprofa,
Sociedad Anonima
Laboratorios Parke
Davis, S.L.
Laboratorios Pfizer
Ltda.
Laboratórios Pfizer,
Lda.
Lothian Developments V
SPRL
MED Urological,
Inc.
Mederio AG
Meridica Limited
Monterey Kelp
Corporation
MTG Divestitures Handels
GmbH
MTG Divestitures
Limited
MTG Divestitures
LLC
Nefox Farma, S.A
Nostrum Farma, S.A
NPF YK
O.C.T. (
Omni Laboratories
Inc
Orsim
P& UFSC, Inc
PanServ Personalberatungs- und
Anzeigenservice
GmbH
Parke Davis & Co. Limited Isle of
BANKS
JP Morgan Chase
Telephone: 800-242-7338
The bank requires an account number which could not be obtained. No credit facilities were reported in the Company's annual report.
PAYMENT HISTORY
Payment History for
Capsugel Division,
BUSINESS
DATE LAST PAYMENT CREDIT BALANCE
CUR 1- 31- 61-
CATEGORY
REPTD
---------- ----- ----- ------- --------
-------- --- --- --- --- --- --------
AIR TRANS
07-04 07-01 0000000 24200
24200 21 6
6 10 57
CUST 23 YR
ELEC DISTR 07-05 00-00 NET 30 0
0 0 0
0 0 0
PROMPT
ELEC EQUIP 07-05 00-00 NET 30 0
0 0 0
0 0 0
CUST 10 YR
ELEC EQUIP 07-05 07-05 CONTRCT 82500 6400
100 0 0 0 0
FINCL SVCS 07-06 07-06 CONTRCT 0 0
0 0 0
0 0 SATSFTRY
FREIGHT
07-04 06-05 VARIED 100 0
0 0 0
0 0
MACH DISTR 07-04 07-04 1/10N30 3800 3000
38 11 0
51 0 CUST
6 YR
PACKAGING
07-06 00-00 NET 30 0 0
0 0 0
0 0 CUST
4 YR
PRNTG& PUBL 07-06 00-00 VARIED 200
200 0 50
49 1 0
SAFTY PROD 07-05 00-00 NET 30 1100
0 0 0
0 0 0
CUST 1 YR
TRANSPORTN 07-04 00-00 NET 30 200
0 0 0
0 0 0
CUST < 1 Y
AIR TRANS
06-11 00-00 NET 30 17600 8700
77 12 1
1 9 CUST 22 YR
BUS SERVCS 04-09 04-07 NET 30 0
0 0 0
0 0 0
COMMUN SVC 06-08 00-00 NET 20 600
300 100 0 0
0 0 WRITE-OFF
ELEC DISTR 04-09 00-00 NET 30 0
0 0 0
0 0 0
PROMPT
ELEC DISTR 04-09 00-00 NET 30 0
0 0 0 0 0
0 PROMPT
HEATNG& A/C 06-12 00-00 NET 30 3700
1400 0 0
0 100 0
SOAP
04-06 00-00 2/10N30 100
100 100 0 0
0 0
CURRENT QUARTER 87900 9600
79 4 1
16 0
Payment Trends
INDUSTRY BUSINESS BALANCE
CUR 1- 31- 61-
DATE CUR DBT
DBT $ % 30 60 90 91+
-------- ---
--- --- --------
--- ---
--- ---
20070600 0 8
13 9500 80 4 0 16 0
20070500 0 7
21 9400 22 62 0 16 0
20070400 0 16
7 15600 89 2 0 9 0
20070300 0 17
20 23800 58 1
35 6 0
20070200 0 18
13 18700 46 46 0 8 0
20070100 0 8
3 25400 94 0 4 2
Payment History - Quarterly Averages
BALANCE
CUR 1- 31- 61-
QUARTER
YEAR DBT $
%
30 60 90 91+
-------- ------ ---
-------- --- --- ---
--- ---
First
2007 15 19400 61 16 15 8 0
Fourth
2006 4 15900 92 1 4 3 0
Third
2006 19 2800 0
93 0 7 0
Second 2006 9 4400 40 59 1 0 0
First
2006 14 11400 13 84 3 0 0
FINANCIAL INFORMATION
FINANCIAL FIGURES
Year-End (D/M/Y): 30/04/2006 30/04/2005 30/04/2004
Consolidated
Consolidated Consolidated
Sales / Revenues 104,241 20,747 10,036
Interest Income - -2,695 -717
Gross Margin 101,219 19,749 9,965
Operating Income (Loss) 100,688 19,614 9,769
RESULTS
Income before Taxes 4,507 1,281 204
Net Income 100,688 16,919 9,052
ASSETS
Cash and Equivalents 340 134 39
Accounts Receivables 816 214 23
Total Current Assets 1,156 348 62
Total Fixed Assets 918,694 287,287 85,927
Total Assets 919,850 287,635 85,989
LIABILITIES
Trade Creditors 694 150 43
Total Current Liab 694 150 43
Long Term Debt - 3,864 -
Total Long Term Liab - 3,864 -
Total Liabilities 694 4,014 43
EQUITY
Retained Earnings -5,229 -17,726 -1,732
Total Equity 919,156 283,620 85,946
FINANCIAL ANALYSIS
Actual Previous Percentage of total assets
30/04/2006 30/04/2005 30/04/2006
30/04/2005
Cash and Equivalents 340 134 0.04 0.05
Total Current Assets 1,156 348 0.13 0.12
Total Assets 919,850 287,635
100.00 100.00
Total Current Liab 694 150 0.08 0.05
Long Term Debt 0 3,864 0.00 1.34
Total Liabilities 694 4,014 0.08 1.40
Total Equity 919,156 283,620 99.92 98.60
The annual report for the year ended 4/30/2007 has not been filed with the Securities and Exchange Commission.
HISTORY
In 2000, Pfizer acquired
Warner-Lambert. Warner-Lambert traces
its history back to the mid-1800s. In
1856, William R. Warner launched his own drug store in
CURRENT OPERATIONS
NAICS Code: 3254 Pharmaceutical and Medicine Manufacturing
Business Activity:
Pfizer Inc. is engaged as a provider of prescription and over-the- counter medicines for humans and animals.
The Company has developed a wide variety of products which include:
Accupril® (quinapril hydrochloride tablets)
Accuretic® (quinapril HCl/hydrochlorothiazide) tablets
Aricept® (donepezil hydrochloride tablets)*
Aromasin® (exemestane tablets)
Caduet® (amlodipine besylate/atorvastatin calcium)
Camptosar® (irinotecan hydrochloride injection)
Cardura® (doxazosin mesylate)
Celebrex® (celecoxib)
Cerebyx® (fosphenytoin sodium injection)
ChantixTM (varenicline)
Depo-Medrol® (methylprednisolone acetate injectable suspension, USP)
Depo-Provera® Contraceptive Injection (medroxyprogesterone acetate injectable
suspension)
depo-subQ provera 104TM (medroxyprogesterone acetate injectable suspension)
Detrol® LA (tolterodine tartrate extended release capsules)
Dilantin® (phenytoin, USP)
Ellence® (epirubicin hydrochloride injection)
Exubera® (insulin human [rDNA origin])
Genotropin® (somatropin [rDNA origin] for injection)
Geodon® Oral Capsules (ziprasidone HCl) and Injection (ziprasidone mesylate)
Glucotrol® (glipizide)
Glucotrol XL® (glipizide GITS) extended release tablets
InspraTM (eplerenone)
Lipitor® (atorvastatin calcium) tablets (Lipitor.com en Español)
Lyrica® (pregabalin) capsules
Macugen® (pegaptanib sodium injection)**
Neurontin® (gabapentin)
Norvasc® (amlodipine besylate)
Procardia® (nifedipine)
Procardia XL® (nifedipine GITS extended release tablets)
Rebif® (interferon beta-1a)***
Relpax® (eletriptan HBr)
Rescriptor® (delavirdine mesylate)
Revatio® (sildenafil citrate)
Somavert® (pegvisomant for injection)
Spiriva® HandiHaler® (tiotropium bromide inhalation powder)****
Sutent® (sunitinib malate)
Tikosyn® (dofetilide)
Unasyn® (ampicillin sulbactam)
Vfend® (voriconazole)
Viagra® (sildenafil citrate) tablets (Viagra.com en Español)
Vibramycin® (doxycycline monohydrate, doxycyline calcium, doxycycline hyclate)
Viracept® (nelfinavir mesylate)
Xalatan® (latanoprost ophthalmic solution)
Xanax® (alprazolam tablets, USP)
Xanax XR® (alprazolam extended-release tablets)
Zarontin® (ethosuximide)
Zithromax® (azithromycin)
ZmaxTM (azithromycin extended release)
Zoloft® (sertraline hydrochloride) (Zoloft.com en Español)
Zyrtec® (cetirizine hydrochloride)
ZyvoxTM (linezolid injection, tablets, and for oral suspension)
* Co-promoted with Eisai Inc. under a license from Eisai Co., Ltd., trademark is
owned by Eisai Co., Ltd.
** Co-promoted with OSI Pharmaceuticals, Inc.
*** Co-promoted with Serono, Inc.
**** Co-promoted with Boehringer Ingelheim Corporation
--------------
Animal products include:
Anipryl®
Antirobe®
Rimadyl®
Revolution®
Revolution® 4 Cats
Revolution® 4 Dogs
SimplicefTM
-----------
Capsugel, a division of
Pfizer Inc, located in
Capsugel, oversees facility
EHS program implementation, ensures competency and quality of facility-level
EHS resources (environment, health and safety (EHS)). Capsugel sells empty gelatin capsules, and
also help companies formulate new products, provide key market to market. Research
at this facility will support lipid formulations that enhance delivery for new
pharmaceutical products entering the market.
The above address is the headquarters for the firm. There are also
branch offices located in
The company has veterinary medicine research and development
operations in ow facilities in Henrietta and
Global Manufacturing (PGM) division is headquartered in
PUBLIC RECORD
Document Type : UCC3 AMENDMENT
Document ID : FT_1950007651595
Filing Date : 05/08/2001
Filing Borough :
Debtor : " PFIZER INC."
UNITED STATES
SECURED PARTY INFORMATION
Secured Party : CISCO SYSTEMS CAPITAL CORPORATION
UNITED STATES
UNIFORM COMMERCIAL CODE REPORT
Source : SC SECRETARY OF STATE
Filing Number : 511181027283
Filing Date : 11/18/2005
Expiration Date : 11/18/2010
Filing Type : ORIGINAL
Filing Office : SECRETARY OF STATE/UCC DIVISION
CAPITOL COMPLEX EDGAR BROWN BLDG RM 525
Debtor(s) : CAPSUGEL, A DIVISION OF PFIZER INC
SECURED PARTY OR CREDITOR INFORMATION
Secured Party(s) : RAYMOND LEASING CORPORATION
COLLATERAL INFORMATION
Collateral Type : LEASED EQUIPMENT
UNIFORM COMMERCIAL CODE REPORT
Source : SC SECRETARY OF STATE
FILING INFORMATION
Filing Date : 10/16/2002
Filing Time : 10:02PM
Expiration Date : 10/16/2007
Filing Type : ORIGINAL
Filing Office : SECRETARY OF STATE/UCC DIVISION
CAPITOL COMPLEX EDGAR BROWN BLDG RM 525
Debtor(s) : CAPSUGEL DIVISION OF PFIZER
Secured Party(s) : WELLS
95 ROUTE 17 SOUTH
Collateral Type : EQUIPMENT
----
CIVIL JUDGMENT FILING RECORD
FILING INFORMATION
Filing Type : JUDGMENTS
Filing Office :
Filing Date : 03/27/2000
Debtor : PFIZER CORPORATION
Debtor Type : BUSINESS BUSINESS DEBTOR
Debtor Amount : $4,030
Creditor : NYC DEPARTMENT OF FINANCE
JUDGMENT INFORMATION
Total Amount : $4,030
----
GENERAL COMMENTS
Pfizer Inc. is an old, well established firm, engaged in the development and production of various drugs and medicines for humans and animals. The Company reports a satisfactory financial condition. A payment record was retrieved for the Capsugel Division which is satisfactory.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)